The Q3 outperformance was led by the FilmArray product line which benefited from exceptional demand for molecular-based COVID testing and increasing instrument placements. The Industrial applications segment also returned to growth. Although the routine testing businesses saw an improvement, it continues to trade in the red and, as hospital traffic remains subdued, uncertainty remains with respect to a full recovery. Nonetheless, the FY20 guidance implies that organic sales growth could reach a ....
